Aptevo Therapeutics Inc (APVO)

$0.58

+0.25

(+73.43%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $0.41
    $0.65
    $0.58
    downward going graph

    29.09%

    Downside

    Day's Volatility :36.92%

    Upside

    11.04%

    downward going graph
  • $0.28
    $50.16
    $0.58
    downward going graph

    50.9%

    Downside

    52 Weeks Volatility :99.43%

    Upside

    98.84%

    downward going graph

Returns

PeriodAptevo Therapeutics IncIndex (Russel 2000)
3 Months
-24.55%
0.0%
6 Months
-91.36%
0.0%
1 Year
-98.79%
0.0%
3 Years
-99.94%
-18.2%

Highlights

Market Capitalization
4.4M
Book Value
$9.06
Earnings Per Share (EPS)
-94.4
PEG Ratio
0.0
Wall Street Target Price
13.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-66.79%
Return On Equity TTM
-186.05%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
3.1M
EBITDA
-27.6M
Diluted Eps TTM
-94.4
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-20.18
EPS Estimate Next Year
-8.13
EPS Estimate Current Quarter
-12.84
EPS Estimate Next Quarter
-6.53

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Aptevo Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2270.69%

Current $0.58
Target $13.75

Technicals Summary

Sell

Neutral

Buy

Aptevo Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc
2.11%
-91.36%
-98.79%
-99.94%
-99.89%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc
NA
NA
0.0
-20.18
-1.86
-0.67
NA
9.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc
Buy
$4.4M
-99.89%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Aptevo Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 167.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 205.5% return, outperforming this stock by 305.4%

Institutional Holdings

  • Vanguard Group Inc

    0.05%
  • Tower Research Capital LLC

    0.03%
  • BlackRock Inc

    0.02%

Company Information

aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.

Organization
Aptevo Therapeutics Inc
Employees
40
CEO
Mr. Marvin L. White
Industry
Health Technology

FAQs